Table I.

Rate of infections in available biologic agents for psoriasis, n (%)

Class	Biologics	Infections, overall: biologics/placebo	URTI: biologics/placebo	Nasopharyngitis: biologics/placebo
TNF	Etanercept	NR	51 (13)/25 (13)†	NR
	Adalimumab	235 (29)/89 (22)	59 (7)/14 (4)	73 (8)/37 (8)∗
	Infliximab	125 (42)/30 (40)	135 (15)/41 (14)∗,†	50 (5)/13 (5)∗,†
	Certolizumab	129 (36)/31 (31)∗,†	24 (7)/5 (5)∗,†	50 (14)/12 (12)∗,†
IL-12/IL-23	Ustekinumab	326 (25)/150 (23)∗,†	64 (5)/30 (5)∗,†	105 (8)/29 (8)∗,†
IL-23	Guselkumab	191 (23)/90 (21)∗	41 (5)/19 (5)∗	65 (8)/33 (8)∗
	Tildrakizumab	NR	25 (2)/9 (3)∗,†	120 (10)/20 (6)∗,†
	Risankizumab	131 (22)/26 (13)∗	28 (5)/4 (2)∗	NR
IL-17	Secukinumab	326 (29)/103 (18)∗,†	36 (3)/3 (1)∗,†	125 (11)/45 (8)∗,†
	Ixekizumab	381 (26)/74 (21)∗,†	51 (3)/12 (3)∗,†	119 (8)/28 (8)∗,†
	Brodalumab	NR	112 (5)/40 (6)∗,†	157 (6)/36 (6)∗,†

IL, Interleukin; NR, not reported; TNF, tumor necrosis factor; URTI, upper respiratory tract infection.

^∗Data were collected from 2 pivotal phase 3 trials and are reported as the mean.

^†Combined doses are reported as the mean.